Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis. / Attauabi, Mohamed; Madsen, Gorm Roager; Bendtsen, Flemming; Seidelin, Jakob Benedict; Burisch, Johan.
I: Digestive and Liver Disease, Bind 54, Nr. 9, 2022, s. 1168-1178.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis
AU - Attauabi, Mohamed
AU - Madsen, Gorm Roager
AU - Bendtsen, Flemming
AU - Seidelin, Jakob Benedict
AU - Burisch, Johan
N1 - Publisher Copyright: © 2021
PY - 2022
Y1 - 2022
N2 - Background: The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative colitis (UC) and Crohn's disease (CD) remain unknown. Aims: To perform a meta-analysis regarding vedolizumab as first line of biological therapy for UC or CD. Methods: A systematic review of Medline, EMBASE, and Cochrane databases per December 2020 was undertaken. Meta-analysis was conducted using random-effects models. Results: This systematic review identified 79 eligible studies with 4,520 and 3,494 bio-naïve patients with UC and CD, respectively, and 8,105 and 11,140 bio-exposed patients. Among bio-naïve patients with UC, a total of 40.0% (95%CI 27.0–54.0, I2=86%) and 63.9% (95%CI 47.0–79.2, I2=36%) achieved clinical remission at weeks 14 and 52, respectively. The corresponding rates in CD were 54.0% (95%CI 42.0–66.0, I2=23%), and 61.7% (95%CI 55.2–68.1, I2=0%). Bio-naïvety was associated with a higher probability of clinical remission at week 52 in UC (relative risk (RR)=1.32 (95%CI 1.14–1.53)), while this was only apparent until week 26 in CD (RR=1.60 (95%CI 1.30–1.95)). Finally, bio-naïve UC patients had a lower risk of serious adverse events (RR=0.29 (95%CI 0.09–0.95)). Conclusion: Vedolizumab was found to have a favorable efficacy and safety profile in bio-naïve patients with UC and CD. The findings have implications in the management of IBD.
AB - Background: The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative colitis (UC) and Crohn's disease (CD) remain unknown. Aims: To perform a meta-analysis regarding vedolizumab as first line of biological therapy for UC or CD. Methods: A systematic review of Medline, EMBASE, and Cochrane databases per December 2020 was undertaken. Meta-analysis was conducted using random-effects models. Results: This systematic review identified 79 eligible studies with 4,520 and 3,494 bio-naïve patients with UC and CD, respectively, and 8,105 and 11,140 bio-exposed patients. Among bio-naïve patients with UC, a total of 40.0% (95%CI 27.0–54.0, I2=86%) and 63.9% (95%CI 47.0–79.2, I2=36%) achieved clinical remission at weeks 14 and 52, respectively. The corresponding rates in CD were 54.0% (95%CI 42.0–66.0, I2=23%), and 61.7% (95%CI 55.2–68.1, I2=0%). Bio-naïvety was associated with a higher probability of clinical remission at week 52 in UC (relative risk (RR)=1.32 (95%CI 1.14–1.53)), while this was only apparent until week 26 in CD (RR=1.60 (95%CI 1.30–1.95)). Finally, bio-naïve UC patients had a lower risk of serious adverse events (RR=0.29 (95%CI 0.09–0.95)). Conclusion: Vedolizumab was found to have a favorable efficacy and safety profile in bio-naïve patients with UC and CD. The findings have implications in the management of IBD.
KW - Bio-naïve
KW - First-line
KW - Inflammatory bowel disease
KW - Meta-analysis
KW - Systematic review
U2 - 10.1016/j.dld.2021.11.014
DO - 10.1016/j.dld.2021.11.014
M3 - Review
C2 - 34903497
AN - SCOPUS:85121110647
VL - 54
SP - 1168
EP - 1178
JO - Rendiconti di Gastro-Enterologia
JF - Rendiconti di Gastro-Enterologia
SN - 1590-8658
IS - 9
ER -
ID: 292162150